Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab PK/Safety in Pediatric jPsA and Psoriasis
NCT05252533Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ustekinumab in juvenile psoriatic arthritis (JPsA) and psoriasis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Serum Concentration of Ustekinumab at 16 weeks. Started May 2022; status: completed.
02
Drugs
ustekinumab
03
Conditions
juvenile psoriatic arthritis (JPsA)psoriasis
Beyond the preview
Go deeper on NCT05252533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252533.